专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2012135146A2 ROLE OF IFNG METHYLATION IN INFLAMMATORY BOWEL DISEASE 审中-公开
标题翻译： IFNG甲基化在炎症性皮肤病中的作用
公开(公告)号：WO2012135146A2
公开(公告)日：2012-10-04
申请号：PCT/US2012030616
申请日：2012-03-26
申请人： CEDARS SINAI MEDICAL CENTER , GONSKY REBECCA , DEEM RICHARD , TARGAN STEPHAN R
发明人： GONSKY REBECCA , DEEM RICHARD , TARGAN STEPHAN R
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q2600/154 , C12Q2600/156 , C12Q2600/158
摘要： The invention relates to method of diagnosing susceptibility to inflammatory bowel disease (IBD) in an individual by obtaining a sample from the individual, assaying the sample to determine the presence or absence of one or more risk genetic variants and/or an increase in IFNG DNA methylation. In one embodiment, the present invention provides a method of diagnosing susceptibility to inflammatory bowel disease (IBD) in an individual by obtaining a sample from the individual, assaying the sample to determine the presence or absence of one or more risk genetic variants and/or an increase in IFNG DNA methylation relative to a normal subject, and diagnosing susceptibility to inflammatory bowel disease based on the presence of one or more risk genetic variants and/or an increase in IFNG DNA methylation relative to a normal subject. In another embodiment, the IBD is ulcerative colitis.
摘要翻译：本发明涉及通过从个体获得样品来诊断对个体的炎性肠病易感性（IBD）的方法，测定样品以确定一种或多种风险遗传变异体的存在或不存在和/或IFNG DNA的增加甲基化。在一个实施方案中，本发明提供了通过从个体获得样品来诊断个体中对炎症性肠病（IBD）的易感性的方法，测定样品以确定是否存在一种或多种风险遗传变体和/或相对于正常受试者，IFNG DNA甲基化的增加，以及基于一种或多种风险遗传变异体的存在和/或IFNG DNA甲基化相对于正常受试者的增加诊断对炎性肠病的易感性。在另一个实施方案中，IBD是溃疡性结肠炎。

2. 发明公开

EP2689036A4 METHODS OF DIAGNOSING AND TREATING INTESTINAL GRANULOMAS AND LOW BONE DENSITY IN INFLAMMATORY BOWEL DISEASE 有权
标题翻译：方法的炎症性肠病的诊断和治疗肠道肉芽肿低骨密度
公开(公告)号：EP2689036A4
公开(公告)日：2015-04-15
申请号：EP12765854
申请日：2012-03-26
申请人： CEDARS SINAI MEDICAL CENTER , MCGOVERN DERMOT P , DUBINSKY MARLA C , TAYLOR KENT D , TARGAN STEPHAN R , ROTTER JEROME I
发明人： MCGOVERN DERMOT P , DUBINSKY MARLA C , TAYLOR KENT D , TARGAN STEPHAN R , ROTTER JEROME I
IPC分类号： G01N33/48
CPC分类号： C12Q1/6883 , C12Q2600/118 , C12Q2600/156 , G01N33/6893 , G01N2800/065
摘要： The present invention relates to methods of diagnosing inflammatory bowel disease (IBD) in an individual by determining the presence of at least one risk genetic variant and/or at least one risk serological marker. In one embodiment, the presence of at least one risk genetic variant is indicative of granuloma. In another embodiment, the presence of at least one risk genetic variant is indicative of low bone density (LBD).
摘要翻译：本发明涉及通过确定性采矿诊断在个体炎性肠病（IBD）的至少一个风险变体的遗传和/或至少一个风险血清学标志物的存在的方法。在一个，实施例的至少一个风险基因变体的存在表示肉芽肿。在另一个中，至少一个风险基因变体的存在表示低骨密度实施例（LBD）的。

3. 发明申请

WO2009143278A3 METHODS OF DIAGNOSING AND CHARACTERIZING CANNABINOID SIGNALING IN CROHN'S DISEASE 审中-公开
标题翻译：诊断和表征冠状动脉疾病的CANNABINOID信号的方法
公开(公告)号：WO2009143278A3
公开(公告)日：2010-01-14
申请号：PCT/US2009044720
申请日：2009-05-20
申请人： CEDARS SINAI MEDICAL CENTER , TARGAN STEPHAN R , ROTTER JEROME I , TAYLOR KENT D , UNIV CALIFORNIA , ZIRING DAVID A , BRAUN JONATHAN , WEI BO
发明人： TARGAN STEPHAN R , ROTTER JEROME I , TAYLOR KENT D , ZIRING DAVID A , BRAUN JONATHAN , WEI BO
IPC分类号： G01N33/48
CPC分类号： C12Q1/6883 , C12Q2600/106 , C12Q2600/112 , C12Q2600/156 , C12Q2600/172
摘要： Diagnosis of Crohn's Disease by determining the presence or absence of vapants at the CNR2 (cannabinoid) genetic locus and serological markers is disclosed Methods of diagnosing a Crohn's Disease subtype by determining the presence or absence of one or more risk vapants at the CNR2 5 locus and the presence or absence of ASCA, OmpC, I2 and/or anti-Cbirl antibodies are included
摘要翻译：公开了通过确定CNR2（大麻素）遗传基因座和血清学标记物中存在或不存在蒸气来诊断克罗恩病的方法。通过确定在CNR2 5基因座处存在或不存在一种或多种风险气体来诊断克罗恩病亚型的方法，以及包括ASCA，OmpC，I2和/或抗Cbirl抗体的存在或不存在

4. 发明申请

WO2009052512A3 METHODS OF USING GENETIC VARIANTS TO DIAGNOSE AND PREDICT INFLAMMATORY BOWEL DISEASE 审中-公开
标题翻译：使用遗传变异体诊断和预测炎性肠病的方法
公开(公告)号：WO2009052512A3
公开(公告)日：2009-06-11
申请号：PCT/US2008080526
申请日：2008-10-20
申请人： CEDARS SINAI MEDICAL CENTER , ROTTER JEROME I , TAYLOR KENT D , TARGAN STEPHAN R , MCGOVERN DERMOT P , MEI LING , SU XIAOWEN
发明人： ROTTER JEROME I , TAYLOR KENT D , TARGAN STEPHAN R , MCGOVERN DERMOT P , MEI LING , SU XIAOWEN
IPC分类号： G01N33/48
CPC分类号： C12Q1/6883 , C12Q2600/156 , C12Q2600/158 , C12Q2600/172
摘要： The present invention relates to methods of diagnosing susceptibility to Inflammatory Bowel Disease and subtypes of Inflammatory Bowel Disease. In one embodiment, the present invention provides a method of diagnosing susceptibility to Inflammatory Bowel Disease by determining the presence of one or more risk variants at the DR3 locus, GATA3 locus, SIN(EFS) locus, BTLA locus, LIGHT locus and MAGI2 locus.
摘要翻译：本发明涉及诊断炎症性肠病和炎性肠病亚型的易感性的方法。在一个实施方案中，本发明提供了通过确定DR3基因座，GATA3基因座，SIN（EFS）基因座，BTLA基因座，LIGHT基因座和MAGI2基因座处一种或多种风险变体的存在来诊断对炎症性肠病的易感性的方法。

5. 发明申请

WO2005115469A3 ESTROGEN MODULATION OF IFN-GAMMA-MEDIATED CONDITIONS AND DISEASES 审中-公开
标题翻译： IFN-GAMMA介导的病症和疾病的雌激素调节
公开(公告)号：WO2005115469A3
公开(公告)日：2009-05-14
申请号：PCT/US2005018161
申请日：2005-05-24
申请人： CEDARS SINAI MEDICAL CENTER , GONSKY RIVKAH , TARGAN STEPHAN R
发明人： GONSKY RIVKAH , TARGAN STEPHAN R
IPC分类号： C12N5/08 , A61K31/075 , A61K31/14 , A61K31/56 , A61K35/26 , A61K45/00 , C12N15/00
CPC分类号： A61K31/56 , A61K35/26
摘要： Particular aspects provide methods for: modulating IFN-?-mediated conditions and diseases (e.g. inflammation, HIV/AIDS, etc). Additionally provided are methods for: reducing IFN-? expression or secretion in cultured mammalian cells, comprising culturing in the presence of at least one agent selected from the group consisting of estrogen, estriol, estrone and a SERM; for ex-vivo therapy for an IFN-?-mediated condition or disease, comprising culturing isolated lymphoid cells in the presence of at least one of the above agents; for treating an IFN-?-mediated condition or disease in a mammal, comprising administering to a subject at least one at least one of the above agents; for treating an IFN-?-mediated condition or disorder in a gender-dependent manner; for conferring estrogen-responsive expression using a recombinant SNP IFN-?-179G/T promoter; and for gene therapy using same. Preferably, mammalian cells are human, selected from T cells, PBL, LPMC, and combinations thereof. In particular aspects, the cells are female.
摘要翻译：具体方面提供了调节IFN-α介导的病症和疾病（例如炎症，HIV / AIDS等）的方法。另外提供的方法是：减少IFN- 培养的哺乳动物细胞中的表达或分泌，包括在至少一种选自雌激素，雌三醇，雌酮和SERM的药剂存在下培养; 用于IFN-α介导的病症或疾病的离体治疗，包括在至少一种上述药剂存在下培养分离的淋巴样细胞; 用于治疗哺乳动物的IFN-γ介导的病症或疾病，包括向受试者施用至少一种上述药物中的至少一种; 用于以性别依赖的方式治疗IFN-α介导的病症或障碍; 用于使用重组SNP IFN-α-179G / T启动子赋予雌激素反应性表达; 并使用相同的基因治疗。优选地，哺乳动物细胞是人，选自T细胞，PBL，LPMC及其组合。在特定方面，细胞是雌性的。

6. 发明申请

WO2008106579A3 THE ROLE OF IL-12, IL-23 AND IL-17 RECEPTORS IN INFLAMMATORY BOWEL DISEASE 审中-公开
标题翻译： IL-12，IL-23和IL-17受体在炎症性皮肤疾病中的作用
公开(公告)号：WO2008106579A3
公开(公告)日：2008-12-31
申请号：PCT/US2008055236
申请日：2008-02-28
申请人： CEDARS SINAI MEDICAL CENTER , TARGAN STEPHAN R , ROTTER JEROME I , TAYLOR KENT D
发明人： TARGAN STEPHAN R , ROTTER JEROME I , TAYLOR KENT D
IPC分类号： C07H21/04 , C12Q1/68
CPC分类号： C12Q1/6883 , C12Q2600/112 , C12Q2600/172
摘要： This invention provides methods of diagnosing or predicting susceptibility or protection against Inflammatory Bowel Disease in an individual by determining the presence or absence of genetic variants in the genes for IL-12, IL-23, and/or IL-17 receptors. In one embodiment, a method of the invention is practiced by determining the presence or absence of risk and/or protective haplotypes of IL-12, IL-23, and/or IL-17 receptors.
摘要翻译：本发明通过确定IL-12，IL-23和/或IL-17受体基因中遗传变体的存在或不存在来提供诊断或预测个体易感性或防止炎症性肠病的方法。在一个实施方案中，通过测定IL-12，IL-23和/或IL-17受体的风险和/或保护性单倍型的存在或不存在来实施本发明的方法。

7. 发明申请

WO2006063093A3 METHODS FOR DIAGNOSIS AND TREATMENT OF CROHN'S DISEASE 审中-公开
标题翻译： CROHN病的诊断和治疗方法
公开(公告)号：WO2006063093A3
公开(公告)日：2006-11-30
申请号：PCT/US2005044335
申请日：2005-12-08
申请人： CEDARS SINAI MEDICAL CENTER , TARGAN STEPHAN R , LANDERS CAROL J , YANG HUIYING
发明人： TARGAN STEPHAN R , LANDERS CAROL J , YANG HUIYING
IPC分类号： C12P19/34
CPC分类号： G01N33/6854 , G01N33/6893 , G01N2800/065 , Y10T436/143333
摘要： The inventors have discovered an elevated serum response to CBir1 flagellin in Crohn's disease patients. The present invention relates to methods for diagnosis and treatment of Crohn's disease and/or subtypes of Crohn's disease. Diagnosis is accomplished by determining the presence of the anti-CBir1 expression or determining the presence of anti-CBir1 expression and detection of the presence of pANCA. Treatment methods include antigen-directed therapy targeting CBir1 flagellin and manipulating the bacteria in the colon and/or small intestine.
摘要翻译：本发明人已经发现克罗恩病患者对CBir1鞭毛蛋白的血清反应升高。本发明涉及克罗恩病和/或克罗恩病亚型的诊断和治疗方法。通过确定抗CBIR1表达的存在或确定抗CBir1表达的存在和检测pANCA的存在来实现诊断。治疗方法包括靶向CBir1鞭毛蛋白的抗原定向治疗和操纵结肠和/或小肠中的细菌。

8. 发明申请

WO2010075579A3 METHODS OF PREDICTING MEDICALLY REFRACTIVE ULCERATIVE COLITIS (MR-UC) REQUIRING COLECTOMY 审中-公开
标题翻译：预防药物回顾性检查（MR-UC）要求的方法
公开(公告)号：WO2010075579A3
公开(公告)日：2010-10-14
申请号：PCT/US2009069531
申请日：2009-12-24
申请人： CEDARS SINAI MEDICAL CENTER , ROTTER JEROME I , TAYLOR KENT D , TARGAN STEPHAN R , HARITUNIANS TALIN , MCGOVERN DERMOT P
发明人： ROTTER JEROME I , TAYLOR KENT D , TARGAN STEPHAN R , HARITUNIANS TALIN , MCGOVERN DERMOT P
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q2600/118 , C12Q2600/156 , G01N2800/067
摘要： Disclosed are methods of predicting the development of medically refractory ulcerative colitis (MR-UC) in a patient In one embodiment, disclosed is a method of prognosing ulcerative colitis in an individual by determining the presence or absence of one or more risk variants, where the presence of one or more risk variants is indicative of a severe and/or aggressive form of ulcerative colitis. In another embodiment, the severe form of ulcerative colitis is indicative of MR-UC.
摘要翻译：公开了预测患者医学难治性溃疡性结肠炎（MR-UC）的发展的方法。在一个实施方案中，公开了通过确定一种或多种风险变体的存在或不存在来预测个体中的溃疡性结肠炎的方法，其中一种或多种风险变体的存在指示溃疡性结肠炎的严重和/或侵略性形式。在另一个实施方案中，严重形式的溃疡性结肠炎指示MR-UC。

9. 发明申请

WO2008106451A3 METHODS OF USING SINGLE NUCLEOTIDE POLYMORPHISMS IN THE TL1A GENE TO PREDICT OR DIAGNOSE INFLAMMATORY BOWEL DISEASE 审中-公开
标题翻译： TL1A基因单核苷酸多态性预测或诊断炎性肠病的方法
公开(公告)号：WO2008106451A3
公开(公告)日：2008-11-06
申请号：PCT/US2008055020
申请日：2008-02-26
申请人： CEDARS SINAI MEDICAL CENTER , ROTTER JEROME I , TAYLOR KENT D , DUBINSKY MARLA , TARGAN STEPHAN R
发明人： ROTTER JEROME I , TAYLOR KENT D , DUBINSKY MARLA , TARGAN STEPHAN R
IPC分类号： C12Q1/68 , A01N43/04 , C12M1/34 , C12N15/00
CPC分类号： C12Q1/6883 , C07K16/2875 , C07K2317/76 , C12Q2600/112 , C12Q2600/156 , C12Q2600/158 , C12Q2600/172 , G01N33/6893 , G01N2800/065 , G01N2800/50
摘要： This invention provides methods of diagnosing or predicting susceptibility to Inflammatory Bowel Disease by determining the presence or absence of genetic variants in the TL1A gene. In one embodiment, a method of the invention is practiced by determining the presence or absence of TL1A production following Fc-gamma-R activation. In another embodiment, the invention provides methods of treatment of inflammatory bowel disease by inhibition of TL1A.
摘要翻译：本发明提供了通过确定TL1A基因中是否存在遗传变异来诊断或预测炎性肠病易感性的方法。在一个实施方案中，本发明的方法通过测定Fc-γ-R活化后TL1A产生的存在或不存在来实施。在另一个实施方案中，本发明提供了通过抑制TL1A来治疗炎症性肠病的方法。

10. 发明申请

WO2007117611A3 ENHANCED T CELL RECEPTOR-MEDIATED TUMOR NECROSIS FACTOR SUPERFAMILY AND CHEMOKINE MRNA EXPRESSION IN PERIPHERAL BLOOD LEUKOCYTES IN PATIENTS WITH CROHN'S DISEASE 审中-公开
标题翻译：增强T细胞受体介导的肿瘤坏死因子超家族和CHEMOKINE在外周血白细胞介素的表达与患有慢性疾病的患者
公开(公告)号：WO2007117611A3
公开(公告)日：2008-08-07
申请号：PCT/US2007008597
申请日：2007-04-05
申请人： HITACHI CHEMICAL CO LTD , HITACHI CHEMICAL RES CT INC , CEDARS SINAI MEDICAL CENTER , MITSUHASHI MASATO , TARGAN STEPHAN R
发明人： MITSUHASHI MASATO , TARGAN STEPHAN R
IPC分类号： G01N33/53
CPC分类号： C12Q1/6883 , C12Q2600/106 , C12Q2600/136 , C12Q2600/158
摘要： A method is disclosed for determining whether a human having Crohn's disease is likely to respond to a therapy targeting a TNFSF member or a cytokine by measuring the level of certain mRNAs in response to a stimulus. A method of evaluating the effectiveness of a Crohn's disease therapy in a human is also disclosed. Furthermore, a method of screening compounds for use in the treatment of Crohn's disease is disclosed. A method of monitoring the disease state over time in Crohn's disease patients is also disclosed.
摘要翻译：公开了一种用于通过测量响应于刺激的某些mRNA的水平来确定克罗恩病患者是否可能对靶向TNFSF成员或细胞因子的治疗作出反应的方法。还公开了评估人类克罗恩病治疗有效性的方法。此外，公开了一种筛选用于治疗克罗恩病的化合物的方法。还公开了一种在克罗恩病患者中随时间监测疾病状态的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式